Health care reform; drug safety, value and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act; value of prescription medicines; adult vaccines; pandemic and biodefense funding; Zika funding and countermeasure development; drug importation, including related provisions in H.R. 1245 and S. 469, the Affordable and Safe Prescription Drug Importation Act and S. 64, and H.R. 1480, the Safe and Affordable Drugs from Canada Act; and drug pricing and insulin pricing issues; and Buy American Act implementation issues.
Medicare coverage, coding and reimbursement of pharmaceuticals, including implementation of related provisions included in the Affordable Care Act; and Medicare reimbursement for physicians, including reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B Drug Payment Model; H.R. 242/ S. 41, the Medicare Prescription Drug Price Negotiation Act; Medicare Part D Program; repeal of the Independent Payment Advisory Board and related legislation, S. 260 and H.R. 849.
International intellectual property issues, including those related to UN High Level Panel on Access, issues in India and provisions related to Canada.
Issues related to corporate taxation, including the deduction of interest; 40% excise tax on employer-sponsored health care; and H.R.394/ S. 85, the Restoring Access to Medication Act; issues related to border adjustment tax.
Duration: January 1, 2007
to
July 28, 2017
General Issues: Health Issues , Medicare/Medicaid , Copyright/Patent/Trademark , Taxation/Internal Revenue Code , Medical/Disease Research/Clinical Labs
Spending: about $3,300,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: U.S. Senate, House of Representatives, U.S. Senate,, Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Richard Sullivan Special Assistant to House Majority Leader
Jim McCrery Former Member of Congress, Louisiana 4th; Ranking Member, House Ways and Means Committee; and Member, Joint Committee on Taxation
Former Member of Congress, Louisiana 4th; Ranking Member, House Ways and Means Committee; and Committee Member, Joint Committee on Taxation
Ranking Member, House Ways and Means Cmte
Committee Member, Joint Cmte on Taxation
Drew Goesl Chief of Staff, Rep. Mike Ross; Communications Director, Sen. Blanche Lincoln
Chief of Staff, Rep. Mike Ross; and Communications Director, Sen. Blanche Lincoln
Chief of Staff, Cong. Mike Ross
Communications Dir., Sen. Blanche Lincoln
Sara Franko Legislative Director/AA, Rep. Ted Strickland; AA, Rep. Gerald Kleczka; LD/LA, Rep. Dennis Eckart
Legislative Director/AA, Rep. Ted Strickland; AA, Rep. Gerald Kleczka; and LD/LA, Rep. Dennis Eckart
Aaron K. Cohen Chief of Staff & Legislative Assistant, Sen. John Ensign; Legislative Aide and Legislative Correspondent, Sen. Richard Bryan
Chief of Staff & Leg Asst., Sen. John Ensign
Legislative Aide, Sen. Richard Bryan
Legislative Corresp., Sen. Richard Bryan
Luke Hatzis LD & LA, Cong. Peter Roskam; Republican Clerk, House Rules Committee; Legislative aide, House Republican Conference; Floor Assistant, Speaker J. Dennis Hastert
Legislative Aide, House Republican Conference
Ann Jablon Chief of Staff, Rep. Richard Neal.
Martin Gold Floor Advisor & Counsel, Senate Majority Leader Bill Frist
David Olander Legislative Assistant, Rep. Wally Herger; Tax & Policy Counsel, Rep. Thomas M. Reynolds; Tax Counsel & Chief Tax Counsel, House Committee on Ways and Means
Dena Battle Legislative Director, Rep. Dave Camp; and Legislative Director, Rep. Nick Smith
Leg. Director, Rep. Dave Camp
Leg. Director, Rep. Nick Smith
John O'Neill Policy Director/Counsel, Senate Minority Whip
Tax Counsel, Senate Finance Committee
James Gould Staff Director, Senate Finance Committee
Tucker Shumack Tax/Finance Counsel, Sen Cmte Small Business
LA, Sen Johnny Isakson; LA, Sen Paul Coverdell
Aaron Cohen Chief of Staff & Leg Asst., Sen. John Ensign
Legislavtive Aide, Sen. Richard Bryan
Legislavtive Corresp., Sen. Richard Bryan
Catherine Finley Staff Director, Sen. Aging Committee
Sr. Health Policy Advisor, Sen. Gordon Smith
Sr. Health Policy Advisor, Sen. Olympia Snowe
Staff Director, Senate Aging Committee
John D. Raffelli n/a
Jim Gould n/a
Denise Henry n/a
Shannon Finley n/a
Zahra Buck n/a
David Jones n/a
DAN PAPDOPOULOS n/a
SARA L. FRANKO n/a
Mike Hoak n/a
Denise Henry Morrisey n/a
Kate Abramson n/a
Kate Abramson-Beller n/a
John D. Raffaelli n/a
De'Ana Dow n/a
John D Raffaelli n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
3rd Quarter, 2017
Capitol Counsel LLC terminated an engagement in which they represented Sanofi US Services Inc. on July 28, 2017.
Original Filing: 300898706.xml
Lobbying Issues
Health care reform; drug safety, value and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act; value of prescription medicines; adult vaccines; pandemic and biodefense funding; Zika funding and countermeasure development; drug importation, including related provisions in H.R. 1245 and S. 469, the Affordable and Safe Prescription Drug Importation Act and S. 64, and H.R. 1480, the Safe and Affordable Drugs from Canada Act; and drug pricing and insulin pricing issues; and Buy American Act implementation issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, including implementation of related provisions included in the Affordable Care Act; and Medicare reimbursement for physicians, including reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B Drug Payment Model; H.R. 242/ S. 41, the Medicare Prescription Drug Price Negotiation Act; Medicare Part D Program; repeal of the Independent Payment Advisory Board and related legislation, S. 260 and H.R. 849.
Agencies Lobbied
U.S. Senate
Lobbying Issues
International intellectual property issues, including those related to UN High Level Panel on Access, issues in India and provisions related to Canada.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to corporate taxation, including the deduction of interest; 40% excise tax on employer-sponsored health care; and H.R.394/ S. 85, the Restoring Access to Medication Act; issues related to border adjustment tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, Capitol Counsel LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on July 20, 2017.
Original Filing: 300897096.xml
Lobbying Issues
Health care reform; drug safety, value and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act; value of prescription medicines; adult vaccines; pandemic and biodefense funding; Zika funding and countermeasure development; drug importation, including related provisions in H.R. 1245 and S. 469, the Affordable and Safe Prescription Drug Importation Act and S. 64, and H.R. 1480, the Safe and Affordable Drugs from Canada Act; and drug pricing and insulin pricing issues; and Buy American Act implementation issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, including implementation of related provisions included in the Affordable Care Act; and Medicare reimbursement for physicians, including reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B Drug Payment Model; H.R. 242/ S. 41, the Medicare Prescription Drug Price Negotiation Act; Medicare Part D Program; repeal of the Independent Payment Advisory Board and related legislation, S. 260 and H.R. 849.
Agencies Lobbied
U.S. Senate
Lobbying Issues
International intellectual property issues, including those related to UN High Level Panel on Access, issues in India and provisions related to Canada.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to corporate taxation, including the deduction of interest; 40% excise tax on employer-sponsored health care; and H.R.394/ S. 85, the Restoring Access to Medication Act; issues related to border adjustment tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, Capitol Counsel LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on July 10, 2017.
Original Filing: 300882882.xml
Lobbying Issues
Health care reform; drug safety, value and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act; implementation of the 340B Drug Pricing Program; value of prescription medicines; adult vaccines; pandemic and biodefense funding; Zika funding and countermeasure development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, including implementation of related provisions included in the Affordable Care Act; and Medicare reimbursement for physicians, including reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B Drug Payment Model; H.R. 242/ S. 41, the Medicare Prescription Drug Price Negotiation Act; Medicare Part D Program; Medicare chronic care reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
International intellectual property issues, including those related to UN High Level Panel on Access, issues in India and provisions related to Canada.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to corporate taxation, including the deduction of interest; 40% excise tax on employer-sponsored health care; and H.R.394/ S. 85, the Restoring Access to Medication Act; issues related to regulations on inversions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, Capitol Counsel LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on Jan. 18, 2017.
Original Filing: 300848392.xml
Lobbying Issues
Health care reform; drug safety, value and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act; implementation of the 340B Drug Pricing Program; value of prescription medicines; adult vaccines; pandemic and biodefense funding; Zika funding and countermeasure development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, including implementation of related provisions included in the Affordable Care Act; and Medicare reimbursement for physicians, including reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B Drug Payment Model, including related provisions in H.R.5122, to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models; S. 31/H.R. 3016, the Medicare Prescription Drug Price Negotiation Act; Medicare Part D Program; Medicare chronic care reform, including related provisions in S. 3504, the Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
International intellectual property issues, including those related to UN High Level Panel on Access, issues in India and provisions related to Canada.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to corporate taxation, including the deduction of interest; 40% excise tax on employer-sponsored health care; and HR 1270 and S 709, the Restoring Access to Medication Act; issues related to regulations on inversions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2016
In Q3, Capitol Counsel LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on Oct. 20, 2016.
Original Filing: 300839947.xml
Lobbying Issues
Health care reform; drug safety, value and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act; implementation of the 340B Drug Pricing Program; value of prescription medicines; adult vaccines; pandemic and biodefense funding; Zika funding and countermeasure development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, including implementation of related provisions included in the Affordable Care Act; and Medicare reimbursement for physicians, including reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B Drug Payment Model; S. 31/H.R. 3016, the Medicare Prescription Drug Price Negotiation Act; Medicare Part D Program; Medicare Chronic Care Reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
International intellectual property issues, including those related to UN High Level Panel on Access, issues in India and provisions related to Canada.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to corporate taxation, including the deduction of interest; 40% excise tax on employer-sponsored health care; and HR 1270 and S 709, the Restoring Access to Medication Act; issues related to regulations on inversions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2016
In Q2, Capitol Counsel LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on July 19, 2016.
Original Filing: 300813146.xml
Lobbying Issues
Health care reform; drug safety, value and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act; implementation of the 340B Drug Pricing Program; value of prescription medicines; adult vaccines; pandemic and biodefense funding.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, including implementation of related provisions included in the Affordable Care Act; and Medicare reimbursement for physicians, including reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B Drug Payment Model; S. 31/H.R. 3016, the Medicare Prescription Drug Price Negotiation Act; Medicare Part D Program; Medicare Chronic Care Reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
International intellectual property issues and provisions related to Canada Promise Doctrine.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to corporate taxation, including the deduction of interest; 40% excise tax on employer-sponsored health care; and HR 1270 and S 709, the Restoring Access to Medication Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2016
In Q1, Capitol Counsel LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on April 20, 2016.
Original Filing: 300800016.xml
Lobbying Issues
Health care reform; drug safety, value and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act; implementation of the 340B Drug Pricing Program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, including implementation of related provisions included in the Affordable Care Act; and Medicare reimbursement for physicians, including reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B Drug Payment Model.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmaceutical patent issues, including related provisions in HR 9, the Innovation Act, and S 1137 the PATENT Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to corporate taxation, including the deduction of interest.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2015
In Q4, Capitol Counsel LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on Jan. 20, 2016.
Original Filing: 300778289.xml
Lobbying Issues
Health care reform; drug safety, value and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, and dual-eligible demonstrations, including implementation of related provisions included in the Affordable Care Act; and Medicare reimbursement for physicians.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmaceutical patent issues, including related provisions in HR 9, the Innovation Act, and S 1137 the PATENT Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to corporate taxation, including the deduction of interest.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2015
In Q3, Capitol Counsel LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on Oct. 20, 2015.
Original Filing: 300764960.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, and dual-eligible demonstrations, including implementation of related provisions included in the Affordable Care Act; and Medicare reimbursement for physicians, including related provisions in HR 2, the Medicare Access and CHIP Reauthorization Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmaceutical patent issues, including related provisions in HR 9, the Innovation Act, and S 1137 the PATENT Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to corporate taxation, including the deduction of interest.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2015
Capitol Counsel LLC amended a lobbying report for representation of Sanofi US Services Inc. in Q22015 on July 20, 2015.
Original Filing: 300742123.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act (P.O. 11-148 and 111-152) and awareness, diagnosis, and treatment of atrial fibrillation., Medicare coverage, coding and reimbursement of pharmaceuticals, and dual-eligible demonstrations, including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act; and Medicare reimbursement for physicians, including related provisions in H.R. 2, the Medicare Access and CHIP Reauthorization Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, and dual-eligible demonstrations, including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act; and Medicare reimbursement for physicians, including in HR 4302, Protecting Access to Medicare Act of 2014
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmaceutical patent issues, including related provisions in HR 9, the Innovation Act, and S 1137 the PATENT Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2015
In Q2, Capitol Counsel LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on July 15, 2015.
Original Filing: 300735635.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act (P.O. 11-148 and 111-152) and awareness, diagnosis, and treatment of atrial fibrillation., Medicare coverage, coding and reimbursement of pharmaceuticals, and dual-eligible demonstrations, including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act; and Medicare reimbursement for physicians, including related provisions in H.R. 2, the Medicare Access and CHIP Reauthorization Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, and dual-eligible demonstrations, including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act; and Medicare reimbursement for physicians, including in HR 4302, Protecting Access to Medicare Act of 2014
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Capitol Counsel LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on April 20, 2015.
Original Filing: 300727742.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act (P.O. 11-148 and 111-152) and awareness, diagnosis, and treatment of atrial fibrillation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, and dual-eligible demonstrations, including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act; and Medicare reimbursement for physicians, including in HR 4302, Protecting Access to Medicare Act of 2014
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, Capitol Counsel, LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on Jan. 19, 2015.
Original Filing: 300701096.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act (P.L. 111-148 and 111-152) and awareness, diagnosis, and treatment of atrial fibrillation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, and dual-eligible demonstrations, including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act; and Medicare reimbursement for physicians, including lanuage in HR 4302, Protecting Access to Medicare Act of 2014.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, Capitol Counsel, LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on Oct. 15, 2014.
Original Filing: 300677177.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act (P.L. 111-148 and 111-152) and awareness, diagnosis, and treatment of atrial fibrillation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, and dual-eligible demonstrations, including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act; and Medicare reimbursement for physicians.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2014
In Q2, Capitol Counsel, LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on July 21, 2014.
Original Filing: 300668349.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act (P.L. 111-148 and 111-152) and awareness, diagnosis, and treatment of atrial fibrillation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, and dual-eligible demonstrations, including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act; and Medicare reimbursement for physicians, including lanuage in HR 4302, Protecting Access to Medicare Act of 2014.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, Capitol Counsel, LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on April 15, 2014.
Original Filing: 300636101.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act (P.L. 111-148 and 111-152) and awareness, diagnosis, and treatment of atrial fibrillation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, and dual-eligible demonstrations, including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act; and Medicare reimbursement for physicians, including lanuage in HR 4302, protecting access to Medicare Act of 2014, HR 4015 and S.2000, SGR Repeal and Medicare Provider Payment Modernization Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, Capitol Counsel, LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on Jan. 22, 2014.
Original Filing: 300627106.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act (P.L. 111-148 and 111-152) and awareness, diagnosis, and treatment of atrial fibrillation, and pharmaceutical compounding, including related provisions in S. 959, Pharmaceutical Compounding Quality, Security and Accountability Act, and H.R. 3204, Drug Quality and Security Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, and dual-eligible demonstrations, including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act; and Medicare reimbursement for physicians.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, Capitol Counsel, LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on Oct. 21, 2013.
Original Filing: 300602598.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act (P.L. 111-148 and 111-152) and awareness, diagnosis, and treatment of atrial fibrillation, and pharmaceutical compounding, including related provisions in S. 959, Pharmaceutical Compounding Quality and Accountability Act, and House discussion draft legislation to amend section 503A of the Federal Food, Drug, and Cosmetic Act with respect to pharmacy compounding; and HR 3204, Drug Quality & Security Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, and dual-eligible demonstrations, including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act; and Medicare reimbursement for physicians.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, Capitol Counsel, LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on July 22, 2013.
Original Filing: 300584534.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act (P.L. 111-148 and 111-152) and awareness, diagnosis, and treatment of atrial fibrillation, and pharmaceutical compounding, including related provisions in S. 959, Pharmaceutical Compounding Quality and Accountability Act, and House discussion draft legislation to amend section 503A of the Federal Food, Drug, and Cosmetic Act with respect to pharmacy compounding.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, and dual-eligible demonstrations, including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act; and Medicare reimbursement for physicians.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, Capitol Counsel, LLC lobbied for Sanofi US Services Inc. , earning $90,000. The report was filed on April 22, 2013.
Original Filing: 300561466.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of chronic diseases; implementation of related provisions in the Affordable Care Act (P.L. 111-148 and 111-152) and awareness, diagnosis, and treatment of atrial fibrillation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, and dual-eligible demonstrations, including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act; and Medicare reimbursement for physicians.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, Capitol Counsel, LLC lobbied for Sanofi US Services Inc. (fka sanofi-aventis U.S. Inc.) , earning $90,000. The report was filed on Jan. 22, 2013.
Original Filing: 300541395.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of chronic diseases; implementation of related provisions in the Affordable Care Act (P.L. 111-148 and 111-152) and, with respect to atrial fibrillation, H.RES.295 Promoting increased awareness, diagnosis, and treatment of atrial fibrillation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, and dual-eligible demonstrations, including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act; and Medicare reimbursement for physicians.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. Inc. , earning $90,000. The report was filed on Oct. 22, 2012.
Original Filing: 300520799.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of chronic diseases; implementation of related provisions in the Affordable Care Act (P.L. 111-148 and 111-152) and, with respect to atrial fibrillation, H.RES.295 Promoting increased awareness, diagnosis, and treatment of atrial fibrillation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals, dual-eligible demonstrations, including eligible demonststrations including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act; and Medicare reimbursement for physicians.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. Inc. , earning $90,000. The report was filed on July 20, 2012.
Original Filing: 300497215.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of chronic diseases; implementation of related provisions in the Affordable Care Act (P.L. 111-148 and 111-152) and, with respect to AF, H.RES.295 Promoting increased awareness, diagnosis, and treatment of atrial fibrillation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. Inc. , earning $90,000. The report was filed on April 20, 2012.
Original Filing: 300469505.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of chronic diseases; implementation of related provisions in the Affordable Care Act (P.L. 111-148 and 111-152) and, with respect to AF, H.RES.295 Promoting increased awareness, diagnosis, and treatment of atrial fibrillation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. Inc. , earning $90,000. The report was filed on Jan. 20, 2012.
Original Filing: 300447816.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of heart disease, stroke, atrial fibrillation (AF) and other cardiovascular diseases and womens cancer issues; implementation of related provisions in the Affordable Care Act (P.L. 111-148 and 111-152) and, with respect to AF, H.RES.295 Promoting increased awareness, diagnosis, and treatment of atrial fibrillation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. Inc. , earning $90,000. The report was filed on Oct. 18, 2011.
Original Filing: 300418199.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of heart disease, stroke, atrial fibrillation (AF) and other cardiovascular diseases and womens cancer issues; implementation of related provisions in the Affordable Care Act (P.L. 111-148 and 111-152) and, with respect to AF, H.RES.295 Promoting increased awareness, diagnosis, and treatment of atrial fibrillation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. Inc. , earning $90,000. The report was filed on July 20, 2011.
Original Filing: 300402596.xml
Lobbying Issues
Health care reform; drug safety and reimbursement; prevention, diagnosis and treatment of heart disease, stroke, atrial fibrillation (AF) and other cardiovascular diseases and womens cancer issues; implementation of related provisions in the Affordable Care Act (P.L. 111-148 and 111-152) and, with respect to AF, H.RES.295 Promoting increased awareness, diagnosis, and treatment of atrial fibrillation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. Inc. , earning $90,000. The report was filed on April 18, 2011.
Original Filing: 300366152.xml
Lobbying Issues
Health care reform; drug safety, access, pricing and coverage; comparative effectiveness; prevention, diagnosis, and treatment of heart disease, stroke and other cardiovascular diseases in women; and women's cancer issues; implementation of related provisions in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage and coding and reimbursement of pharmaceuticals including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. Inc. , earning $90,000. The report was filed on Jan. 20, 2011.
Original Filing: 300351561.xml
Lobbying Issues
Health care reform; drug safety, access, pricing and coverage; comparative effectiveness; prevention, diagnosis, and treatment of heart disease, stroke and other cardiovascular diseases in women; and women's cancer issues; implementation of related provisions in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act; Revisions to 340B drug discount program in HR 4994, Medicare & Medicaid Extenders Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage and coding and reimbursement of pharmaceuticals including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. Inc. , earning $90,000. The report was filed on Oct. 14, 2010.
Original Filing: 300313003.xml
Lobbying Issues
Health care reform; drug safety, access, pricing and coverage; comparative effectiveness; prevention, diagnosis, and treatment of heart disease, stroke and other cardiovascular diseases in women; and women's cancer issues; implementation of related provisions in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act; Proposed revisions to 340B drug discount program in amendements to HR 4213, American Jobs and Closing Tax Loopholes Act, and S.3793, Job Creation and Tax Cuts Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage and coding and reimbursement of pharmaceuticals including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. Inc. , earning $90,000. The report was filed on July 19, 2010.
Original Filing: 300294285.xml
Lobbying Issues
Health care reform; drug safety, access, pricing and coverage; comparative effectiveness; follow-on biologics; prevention, diagnosis, and treatment of heart disease, stroke and other cardiovascular diseases in women; and women's cancer issues; proposed revisions to the 340B program, including implementation of related provisions in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals and Medicare Part D coverage gap and discount program including implementation of related provisions included in P.L. 111-148, Patient Protection and Affordable Care Act and P.L. 111-152, Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. Inc. , earning $90,000. The report was filed on April 20, 2010.
Original Filing: 300271088.xml
Lobbying Issues
Health care reform; drug safety, access, pricing and coverage; comparative effectiveness; follow-on biologics; prevention, diagnosis, and treatment of heart disease, stroke and other cardiovascular diseases in women; and women's cancer issues; proposed revisions to the 340B program, including related provisions in HR 3590, Patient Protection and Affordable Care Act and HR 4872, Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals and Medicare Part D coverage gap and discount program provisions included in HR 3590, Patient Protection and Affordable Care Act and HR 4872, Health Care and Education Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. Inc. , earning $90,000. The report was filed on Jan. 20, 2010.
Original Filing: 300246279.xml
Lobbying Issues
Health Care Reform; Drug safety and comparative effectiveness; and follow-on biologics; prevention, diagnosis, and treatment of heart disease, stroke and other cardiovascular diseases in women; and women's cancer issues, including related provisions in House and Senate comprehensive health reform legislation; HR 3962, Affordable Health Care for America Act; and HR 3590, Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals and Medicare Part D coverage gap provisions included in HR 3962, Affordable Health Care for America Act and HR 3590, Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. Inc. , earning $60,000. The report was filed on Oct. 20, 2009.
Original Filing: 300221444.xml
Lobbying Issues
Health Care Reform; Drug safety and comparative effectiveness; and follow-on biologics; prevention, diagnosis, and treatment of heart disease, stroke and other cardiovascular diseases in women; and women's cancer issues, including related provisions in House and Senate comprehensive health reform legislation, HR 3200 and S. 1679, America's Affordable Health Choices Act and the Senate Finance Committee's America's Healthy Future Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals and Medicare Part D coverage gap provisions included in HR 3200 and S. 1679, America's Affordable Health Choices Act and the Senate Finance Committee's America's Healthy Future Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. Inc. , earning $60,000. The report was filed on July 16, 2009.
Original Filing: 300180111.xml
Lobbying Issues
Health care reform:Drug safety and comparative effectiveness; and follow-on biologics; prevention, diagnosis, and treatment of heart disease, stroke and other cardiovascular diseases in women; and women's cancer issues, including related provisions in draft House and Senate comprehensive health reform legislation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage, coding and reimbursement of pharmaceuticals.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. Inc. , earning $60,000. The report was filed on April 20, 2009.
Original Filing: 300162101.xml
Lobbying Issues
Health care reform: Federal Food, Drug and Cosmetic Act Issues, including drug safety and comparative effectiveness, and follow-on biologics; prevention, diagnosis, and treatment of heart disease, stroke and other cardiovascular diseases in women; and women's cancer issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage coding and reimbursement of pharmaceuticals.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
Capitol Counsel, LLC amended a lobbying report for representation of sanofi-aventis U.S. Inc. in Q42008 on Feb. 2, 2009.
Original Filing: 300136328.xml
Lobbying Issues
Health care reform: Federal Food, Drug and Cosmetic Act Issues, including drug safety and comparative effectiveness, follow-on biologics and related provisions in HR1956, Patient Protection and Innovative Biologic Medicines Act, HR 5629, Pathway for Biosimilars Act, and S. 1695, Biologics Price Competition and Innovation Act, and cardiovascular issues, including provisions in HR1014 and S.573, bills to amend The Federal Food, Drug, and Cosmetic Act and The Public Health Service Act to improve the prevention, diagnosis, and treatment of heart disease, stroke and other cardiovascular diseases in women; and women's cancer issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage coding and reimbursement of pharmaceuticals, deep vein thrombosis issues, and use of compendia in Medicare, including related provision in S. 3101 and HR 6331, Medicare Improvements for Patients and Providers Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
In Q4, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. LLC , earning $60,000. The report was filed on Jan. 21, 2009.
Original Filing: 300133051.xml
Lobbying Issues
Health care reform: Federal Food, Drug and Cosmetic Act Issues, including drug safety and comparative effectiveness, follow-on biologics and related provisions in HR1956, Patient Protection and Innovative Biologic Medicines Act, HR 5629, Pathway for Biosimilars Act, and S. 1695, Biologics Price Competition and Innovation Act, and cardiovascular issues, including provisions in HR1014 and S.573, bills to amend The Federal Food, Drug, and Cosmetic Act and The Public Health Service Act to improve the prevention, diagnosis, and treatment of heart disease, stroke and other cardiovascular diseases in women; and women's cancer issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage coding and reimbursement of pharmaceuticals, deep vein thrombosis issues, and use of compendia in Medicare, including related provision in S. 3101 and HR 6331, Medicare Improvements for Patients and Providers Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. LLC , earning $60,000. The report was filed on Oct. 17, 2008.
Original Filing: 300099367.xml
Lobbying Issues
Health care reform: Federal Food, Drug and Cosmetic Act Issues, including drug safety and comparative effectiveness, follow-on biologics and related provisions in HR1956, Patient Protection and Innovative Biologic Medicines Act, HR 5629, Pathway for Biosimilars Act, and S. 1695, Biologics Price Competition and Innovation Act, and cardiovascular issues, including provisions in HR1014 and S.573, bills to amend The Federal Food, Drug, and Cosmetic Act and The Public Health Service Act to improve the prevention, diagnosis, and treatment of heart disease, stroke and other cardiovascular diseases in women; and women's cancer issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage coding and reimbursement of pharmaceuticals, deep vein thrombosis issues, and use of compendia in Medicare, including related provision in S. 3101 and HR 6331, Medicare Improvements for Patients and Providers Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. LLC , earning $60,000. The report was filed on July 21, 2008.
Original Filing: 300077619.xml
Lobbying Issues
Health care reform: Federal Food, Drug and Cosmetic Act Issues, including drug safety and comparative effectiveness, follow-on biologics and related provisions in HR1956, Patient Protection and Innovative Biologic Medicines Act, HR 5629, Pathway for Biosimilars Act, and S. 1695, Biologics Price Competition and Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage coding and reimbursement of pharmaceuticals, deep vein thrombosis issues, and use of compendia in Medicare, including related provision in S. 3101 and HR 6331, Medicare Improvements for patients and Providers Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
In Q1, Capitol Counsel, LLC lobbied for sanofi-aventis U.S. LLC , earning $90,000. The report was filed on April 22, 2008.
Original Filing: 300056457.xml
Lobbying Issues
Federal Food, Drug and Cosmetic Act issues, including follow-on biologics, drug safety and reimportation of prescription drugs.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare coverage coding and reimbursement of pharmaceuticals and Medicaid drug rebate, including related provisions in H.R.4 and S.3 Medicare Prescription Drug Price Negotiation Act of 2007; H.R. 3162 Children's Health and Medicare Protection Act of 2007; H.R. 976 Small Business Tax Relief Act of 2007
Agencies Lobbied
U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...